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ABSTRACT 
Background: Polyethylene glycol (PEG) solutions, with or without osmotic 
agents, are used to empty the large intestine before procedures such as colo- 
noscopy or colonic surgery. Data concerning the effectiveness of vitamin C as 
an ingredient in colonic preparations are scant. 
Objective: The aim of this article was to assess the effectiveness, acceptabil- 
ity, and tolerability of 6 preparations of a standard PEG electrolyte solution con- 
taining different doses of PEG, vitamin C (as an osmotic agent), and sodium sul- 
fate in colonic cleansing. 
Methods: This double-blind, randomized, 2-period crossover study was con- 
ducted at the Lariboisi~re Hospital, Paris, France. Healthy adult volunteers were 
randomly assigned to receive 2 of 6 colonic cleansing preparations, each contain- 
ing different doses of PEG (100 or 125 g/L), vitamin C (0, 5, or 10 g/L, in the form 
of sodium ascorbate, ascorbic acid, or a mixture of both), and sodium sulfate (5 
or 7.5 g/L), diluted in water to a volume of 2 L. Study drug administration was sep- 
arated by a washout period of 7 to 15 days, after which the volunteers received 
an alternate preparation. Stools were collected for 10 hours after the start of solu- 
tion ingestion. The primary efficacy end point was stool volume. Secondary end 
points included acceptability of taste, assessed using a 100-mm visual analog 
scale 0gAS) (0 = excellent to 100 = execrable), taste criteria (saltiness, acidity, and 
sweetness, assessed on a 4-point Likert-type scale [0 = very pleasant o 3 = intol- 
erable]) and tolerability (clinical effects [changes in body weight, blood pressure, 
heart rate, and nausea and vomiting] and biologic effects [changes in serum elec- 
trolytes, creatinine, hematocrit, and ascorbic acid]). 
Results: Thirty volunteers (15 men, 15 women; mean [SD] age, 29.8 [8.2] years 
[range, 20-45 years]) were enrolled and completed the study. Mean (SD) stool 
volume obtained with preparations containing 10 g/L of vitamin C did not differ 
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significantly from the volume obtained without vitamin C (2.54 [0.54] L vs 1.93 
[0.62] L; 95% CI, -0.13 to 1.47). Mean (SD) VAS scores for acceptability of taste 
ranged from 54.4 (25.0) (preparation E) to 74.4 (20.1) (preparation C) (P = 0.03 
preparation E vs all other preparations). The only significant difference in taste 
criteria was in acidity, with preparation A being the least acidic according to 
patients' ratings on the VAS (1.4 [0.7] vs 1.8 [0.4] [mean of the other 5 prepara- 
tions combined]; P = 0.04 preparation A vs all other preparations). Mild dehy- 
dration occurred in 6 subjects (1 for each preparation). No clinical or biological 
adverse ffects were found. 
Conclusions: In this study of 6 colonic cleansing preparations in healthy vol- 
unteers, the use of high-dose vitamin C as an osmotic agent in addition to PEG 
did not significantly increase stool output. All 6 preparations were well tolerat- 
ed. (Curt Ther Res Clin Exp. 2005;66:486-500) Copyright © 2005 Excerpta Medica, 
Inc. 
Key words: vitamin C, stool output, acceptability, taste, polyethylene glycol 
solution, colonic preparation, ascorbate, ascorbic acid. 
INTRODUCTION 
The diagnostic value of colonoscopy is dependent on the ability to achieve ade- 
quate colon preparation, characterized by the absence of fecal residue in the 
large intestine, to maximize visibility for the endoscopist. 1 For >20 years, iso- 
osmotic polyethylene glycol (PEG) solutions have been used for colon cleansing 
before colonoscopy, double-contrast barium enema, or colon surgery. 2~s Despite 
the well-established ffectiveness and tolerability of these preparations, ome 
patients are unable to drink the large volume required (___4 L) over a short period 
of time (up to 1 L/h), as well as when a 2-step procedure is used. 4,6 Some patients 
also find the taste of the solutions unpleasant. 4~ Several attempts have been 
made to reduce the required volume by adding stimulant laxatives, such as 
senna, 5bisacodyl, 7 or other osmotic agents (eg, mannitol, magnesium, sodium 
salts), with variable results in terms of acceptability of taste. 4~s 
The most widely used osmotic agent worldwide, sodium phosphate (solution 
or tablet), exerts its action by drawing water from the body into the large intes- 
tine. 2-4,7,8 In several randomized, controlled, investigator-blinded trials en- 
rolling >1300 patients, sodium phosphate was found to be similarly effective 
and better accepted because of the low volume (2 L vs up to 6 L) required to 
clean the large intestine compared with standard PEG electrolyte solu- 
tions. 3,4,7-9 Moreover, in randomized, single-blind trials in >1300 patients requir- 
ing colonoscopy for colon cancer screening, the use of oral sodium phosphate 
was associated with the lowest rate of need for repeat endoscopy due to in- 
adequate cleansing, together with a low cost per patient, compared with stan- 
dard PEG solutions (between-group differences, 65% and 10%-15%, respec- 
tively). 1°-12 Patients' ability to drink the entire preparation, and tolerability, as 
assessed by the prevalences of clinical and biological adverse effects, have 
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been compared in sodium phosphate solutions and standard PEG solu- 
tions. 4'7'8'13 Of the trials involving >1300 patients, some, but not all, trials found 
that a significantly arger proportion of patients (up to 75%) were able to drink 
the required amount of sodium phosphate solutions compared with 40% of 
patients administered standard PEG solutions (P < 0.001). 10-13 Abdominal dis- 
comfort was reported in a significantly higher proportion of patients (15%) 
receiving the PEG solution compared with 7% receiving sodium phosphate solu- 
tion (P < 0.005). 4,8-13 Finally, >90% of patients indicated that they were willing to 
repeat using the oral sodium phosphate preparations compared with 15% to 
30% using the standard PEG solutions. 4,7-13 
However, sodium salts (eg, sodium phosphate, sodium sulfate) have several 
limitations, including their salty taste and their contraindication in patients with 
cardiovascular o renal impairment. 4,8,14 Significant changes in volume of body 
water and serum concentrations of electrolytes, leading to hyperphosphatemia, 
hypocalcemia, hypokalemia, nd/or dehydration with potentially fatal outcomes, 
and colonic mucosal ulcerations have been described in some patients. 4,8,14 
The ideal colonic cleansing preparation would be tolerable in all populations 
of patients, including elderly patients and those with cardiovascular o renal 
impairment. It would be well tolerated and have acceptable required volume 
and taste. Two liters of solution containing sufficient amounts of osmotic agents 
to obtain optimal stool volume (usually >3 L) without a laxative (eg, a senna 
compound) might optimize both colon cleansing and compliance. 15,16 
One possible choice of osmotic agent is ascorbic acid (vitamin C), a 6-carbon, 
ketolactone, water-soluble vitamin structurally related to glucose and other 
hexoses. 17 Vitamin C is readily absorbed from the proximal small intestine 
by 2 saturable, energy- and dose-dependent transporters. 17,18 Because of the 
hexose structure of vitamin C, the unabsorbed fraction may act as an os- 
motic agent in the gut lumen, leading to water excretion and an increase in 
stool volume. 17-21 In 2 open-label studies in 100 healthy volunteers, the ad- 
ministration of an amount of vitamin C larger than physiologically required 
for supplementation (up to 30 g) was associated with low prevalences of 
adverse ffects (eg, kidney stones, abdominal pain, severe acidosis). 17,19 In a 
nonlinear, 2-compartment disposition model of the pharmacokinetic proper- 
ties of vitamin C with saturable, time-constrained intestinal absorption, a sin- 
gle oral dose led to decreased absorption, from 75% with 1 g to 20% with 5 g.20 
After ingestion of 6 g of vitamin C, 1.5 g was absorbed, and the ingestion of 
12 g led to the absorption of 1.9 g of vitamin C. 17'20 
We hypothesized that vitamin C could be used in colonic preparations to 
decrease the volume required for effective cleansing. Based on a literature 
search using MEDLINE (key terms: vitamin C, sodium ascorbate, and colon 
cleansing; years: 1975-2005), data concerning the effectiveness of vitamin C as 
an ingredient in colonic preparations are scant. However, 1 solution containing 
160 g of PEG 3350, 17 g of sodium sulfate, 18 g of ascorbic acid, 7.9 g of sodium 
chloride, and 2.2 g of potassium chloride, diluted in water to a volume of 3 L, 
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has been available in Australia for almost 15 years and has been found to be 
well tolerated (no cases of toxicity have been reported to the manufacturer). 22 
Patients have reported that the solution has an acceptable taste despite con- 
taining a large amount (>27 g) of salt. Moreover, 3 L of this solution has been 
found to be sufficient o achieve ffective colonic cleansing. 23 
A pilot study 24 conducted in 6 healthy adult male volunteers at the Unit of 
Therapeutic Research, Department of Internal Medicine, Lariboisi~re Hospital, 
Paris, France, found that 10 g of vitamin C added to a standard iso-osmotic PEG 
solution increased the stool volume by 35% compared with the standard solu- 
tion alone (2.2 [0.4] L vs 1.4 [0.2] L; P < 0.01). The addition of a third osmotic 
agent (sodium sulfate, 11.1 g) to the vitamin-C-containing solution was associ- 
ated with an almost 2-fold increase from baseline in stool volume (1.4 [0.1] L 
vs 2.7 [0.2] L; P< 0.001). Thus, the combination of PEG, vitamin C, and sodium 
sulfate diluted in water to a volume of 2 L might increase fecal output. 
The aim of this study was to assess the effects of 6 colonic cleansing prepa- 
rations containing different doses of PEG (100 or 125 g/L), vitamin C (0, 5, or 
10 g/L, in the form of sodium ascorbate, ascorbic acid, or a mixture of both), 
and sodium sulfate (5 or 7.5 g/L), diluted in water to a volume of 2 L, before colon- 
oscopy or colon surgery. 
SUBJECTS AND METHODS 
This double-blind, randomized, crossover study was conducted at Lariboisi~re 
Hospital, Paris, France, between April and June 2000. Healthy volunteers aged 20 
to 45 years were recruited from a pool of medical students and staff at the hospi- 
tal. The study protocol was approved by the local ethics committee. Due to ethi- 
cal limitations, we were not authorized by the committee to perform colonoscopy 
to directly assess the efficacy of the tested preparations. Subjects provided writ- 
ten informed consent to participate and were compensated for their participation. 
Study Design 
Diet was standardized 2 days before and during the study to avoid alteration 
of gastrointestinal transit ime. Each volunteer was randomized to receive 2of the 
6 preparations (A to F, with A being the control preparation because it did not 
contain vitamin C) (Table I), 1 during each of 2 study periods separated by a 7- 
to 15-day washout period. Subjects were asked to ingest the entire preparation 
within 2 hours (two 1.25-L glasses every 15 minutes). Compliance with the regi- 
men was visually monitored by one of the study investigators (G.S.) using a timer. 
Assessments 
Efficacy 
Stool volume was measured for 10 hours after the start of solution ingestion. 
Total fecal output at the end of the lO-hour follow-up period was the primary 
end point. 
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Table I. Concentrations (g/L) of the ingredients of 6 colonic cleansing preparations. 
Preparation A Preparation Preparation Preparation Preparation Preparation 
Ingredient (Control) B C D E F 
PEG 100 100 100 100 100 125 
Sodium 
sulfate 7.5 7.5 7.5 7.5 5 7.5 
Ascorbic 
acid 0 5 5 10 5 5 
Sodium 
ascorbate 0 0 5 0 5 5 
PEG = polyethylene glycol. 
Acceptability 
The taste of each preparation was assessed as a secondary end point, using 
a 100-mm visual analog scale (VAS) (0 = excellent to 100 = execrable). Taste cri- 
teria (saltiness, acidity, and sweetness) were assessed on a 4-point Likert-type 
scale (0 = very pleasant to 3 = intolerable). 
Tolerability 
Tolerability was assessed using measurements of body weight, blood pres- 
sure, heart rate, urinary output, volume of excess fluid ingested, and the preva- 
lence of nausea or vomiting during ingestion of the colonic preparation and 
over the 10-hour follow-up period. Two blood samples were drawn--1 just 
before the beginning of preparation i gestion and 1 at the end of the follow-up 
period--to assess changes in serum sodium, potassium, bicarbonate, creati- 
nine, ascorbic acid concentrations (ascorbemia), and hematocrit. 
Statistical Analysis 
Because it would not have been feasible to give all 6 preparations to each vol- 
unteer, statistical analysis was designed to obtain 5 balanced blocks of 
6 treatments. A difference in stool volume of at least 0.8 L between preparations 
with and without vitamin C at a level of significance of 0.05 for 2-sided compari- 
sons between 6 preparations (with an expected residual SD of 0.4 L) was the 
primary end point, based on the pilot study conducted in 6 healthy volunteers, 
with 85% statistical power. Hence, 10 observations were needed per prepara- 
tion, with 2 preparations per subject (block size, k = 2). Thus, 30 subjects 
needed to be enrolled in this crossover study. Results were analyzed according 
to the intent-to-treat principle. Comparisons of primary and secondary end 
points were performed using analysis of variance (ANOVA), followed by the 
Scheffe test adjusted for multiple comparisons when an overall significance was 
detected on ANOVA. Statistical comparisons were performed using StatView ver- 
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sion 5.01 (SAS Institute, Cary, North Carolina). Results are expressed as mean (SD) 
and range, where applicable. 
We were particularly interested in comparing the effects of ascorbic acid 5 g 
versus no ascorbic acid (preparation B vs A), sodium ascorbate 5 g + ascorbic 
acid 5 g versus ascorbic acid 5 g (preparation C vs B), sodium ascorbate 5 g + 
ascorbic acid 5 g versus ascorbic acid 10 g (preparation C vs D), and sodium 
sulfate 7.5 g versus sodium sulfate 5 g (preparation C vs E) (Table I). The rela- 
tionship between stool output and pretreatment body weight was described 
using the Spearman rank correlation coefficient (r). Changes in serum elec- 
trolyte concentrations and hematocrit at the end of preparation i gestion were 
compared using ANOVA followed by the Scheffe test when an overall signifi- 
cance was detected. 
RESULTS 
Demographic Data 
Thirty volunteers (15 men, 15 women) were enrolled and completed the 
study. The mean (SD) age of the study population was 29.8 (8.2) years (range, 
20-45 years), and the mean (SD) weight and height were 70.5 (13.1) kg (range, 
46-100 kg) and 173.2 (9.8) cm (range, 155-195 cm), respectively. No significant 
between-group differences in baseline characteristics, including weight before 
ingestion of the preparations, were found (Table II). 
Twenty-nine volunteers ingested the entire 2-L preparation within 2 hours 
(mean [SD] ingestion time, 115.7 [12.3] minutes [range, 90-145 minutes]); 1sub- 
ject ingested only 1.8 L of preparation B during period 1 but completed the 
study and was therefore included in the intent-to-treat nalysis. Ingestion time 
was not correlated with mean stool output (r, -0.125; P = 0.35). 
Efficacy 
Stool output ranged between 0.65 L (preparation A) and 3.50 L (preparation 
F) and was not correlated with pretreatment body weight (r, 0.007) (Table llI). 
The between-group differences in mean stool volume were not statistically sig- 
nificant. Although preparation F contained 125 g/L of PEG and preparation C
contained 100 g/L of PEG, we did not find any significant differences in stool vol- 
ume between these 2 formulations. Neither period effect nor treatment-period 
interactions were found in this crossover study. 
Acceptability 
As shown in Table I¥, all 6 preparations were given a relatively high mean 
VAS score (---68.9) except preparation E,which contained 5 g/L of sodium sulfate 
and had the lowest mean (SD) VAS score (54.4 [25.0]; P = 0.03 vs all other prepa- 
rations). Likewise, no significant between-preparation differences inVAS scores 
for saltiness or sweetness were found. However, the mean (SD) VAS score for 
acidity was significantly ower for preparation A (1.4 [0.7]), which contained no 
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vitamin C and thus was the least acidic, compared with the other preparations 
(___1.6; all, P = 0.04). 
Tolerability 
Fourteen mild adverse events were reported during the study. As shown in 
Table II, the mean body weight at the end of the 10-hour follow-up period did 
not differ significantly between the 6 preparations or from baseline body weight 
in any group. Body weight loss ranged from 0.25 kg (preparation B) to 1.1 kg 
(preparation D) over the study period. Conversely, mean urinary output de- 
creased by 50% from baseline (330 [155] vs 610 [340] mL, respectively; 95% CI, 
100-880; P = 0.002) at the end of the follow-up period but did not differ signifi- 
cantly between preparations. Overall, the volume of extra fluid ingested by the 
study subjects ranged from 350 (90) to 510 (120) mL and did not differ signifi- 
cantly between preparations. Six subjects (1 for each preparation) indicated 
thirst and asked to drink a large amount (---500 mL) of water after they ingested 
the second liter of preparation. Other adverse vents included abdominal pain, 
noted in 1 subject each with preparations B, C, D, and E; nausea and vomiting, 
in 1 subject each with preparations B and F; and headache, in 1 subject each 
with preparations E and F. Overall, no adverse vents were noted with prepara- 
tion A, 1 with preparations C and D, and 2 with preparations B, E, and F. Due to 
the number of adverse vents reported in the current study, statistical compari- 
son between the 6 preparations could not be performed. These adverse vents 
were transient and did not appear to be related to vitamin C intake. No moder- 
ate or severe adverse vents occurred in any of the treatment groups. 
Blood pressure, heart rate, and weight remained stable in each subject hrough- 
out the study in each treatment group. Mean (SD) systolic blood pressure was 
123 (12) mm Hg before and 123 (16) mm Hg after treatment. Mean (SD) diastolic 
blood pressure was 73 (9) mm Hg before and 73 (7) mm Hg after treatment. Mean 
(SD) heart rate was 71 (9) bpm before and 69 (10) bpm after treatment. Mean (SD) 
patient weight was 70.5 (13.1) kg before and 70.1 (15.5) kg after treatment. 
Minor changes in serum but not urinary electrolyte concentrations were 
observed after treatment completion with all preparations tested (Table V). 
However, the values reported remained within normal limits, and no signifi- 
cant intergroup or intragroup differences were found. Mean (SD) hematocrit 
ranged from 40.5% (3.9%) (preparation E) to 42.1% (4.4%) (preparation D) and 
remained stable in all patients throughout the study period. Mean (SD) serum 
sodium and potassium concentrations ranged from 140 (1.2) mmol/L (prepa- 
ration B) to 145.4 (2.2) mmol/L (preparation F), and from 4.0 (0.2) mmol/L 
(preparation B) to 4.6 (0.2) mmol/L (preparation D), respectively, and did not 
change significantly during the study period. Mean (SD) serum bicarbonate con- 
centrations ranged from 26.3 (3.2) mmol/L (preparation F) to 28.9 (2) mmol/L 
(preparation D) and from 25.5 (1.8) mmol/L (preparation D) to 26.7 (1.5) mmol/L 
(preparation A) before and after treatment, respectively. Mean (SD) serum 
creatinine concentration ranged from 73.5 (13) gmol/L (preparation F) to 
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81.4 (12) 1Jmol/L (preparation D) and did not vary significantly throughout the 
study. Overall, the changes observed in serum electrolyte concentrations and he- 
matocrit did not differ significantly between the 6 colonic cleansing preparations. 
The mean (SD) serum vitamin C concentrations were 67.5 (97.4) mmol/L with 
preparation A (no vitamin C), 141 (75) mmol/L with preparation B (5 g/L ascor- 
bic acid), and 189.7 (52.6) mmol/L with preparation E (5 g/L ascorbic acid and 
5 g/L sodium ascorbate). 
DISCUSSION 
The tolerability and volume of a cleansing preparation might limit its accept- 
ability and, therefore, efficacy of colonic cleansing. 25-27 A preparation volume of 
2 L was chosen based on previous reports establishing that at least 3 L of stool 
was required to achieve effective colonic cleansing. 15,16 The combinations of 
osmotic agents used in the 6 preparations tested in the present study were cho- 
sen to achieve this outcome. 
The effects of vitamin C, in the form of ascorbic acid, sodium ascorbate, or a 
mixture of both, on stool volume was assessed because its hexose structure, 
tolerability, and saturable absorption led us to assume that this vitamin can be 
administered at high doses and act as an osmotic agent in the gut lumen, 
thereby increasing stool volume. 17-21 The differences in serum vitamin C con- 
centration were not linear with the dose of vitamin C, and were variable, which 
agrees with the previously described nonlinear, saturable pharmacokinetic prop- 
erties of vitamin C in humans. 2° The prevalence of ascorbemia (141 [75] mmol/L 
with preparation C vs 154.4 [46] mmol/L with preparation D) was not correlated 
with the use of preparations in which half of the ascorbic acid was replaced 
with sodium ascorbate, suggesting that both formulations hare the same 
absorptive capacity across the human small intestine. Acidity as reported by 
the volunteers was not related to ascorbemia (data not shown). Based on the 
literature search, this is the first report of the effect of vitamin C on fecal out- 
put in humans. Although stool output obtained with the combinations pro- 
viding the highest stool output (preparations C, D, and F; Table If) did not 
achieve the outcome of 3 L of stool, the use of 20 g of vitamin C with a stan- 
dard 2-L volume of solution containing PEG 200 g and sodium sulfate 15 g 
increased stool volume by up to 1500 mL in some subjects compared with 
control. 
All 6 preparations in this study were well tolerated. Abdominal pain was 
reported in 4 subjects, while nausea and vomiting occurred in 2 subjects. 
Fermentation of ascorbate mediated by colonic bacteria, such as Escherichia 
coli, has been previously reported. 28 Ascorbate might be fermented in the 
large bowel, producing hydrogen, carbon dioxide, short-chain fatty acids, 
and protons, which are readily absorbed but are also likely to produce 
abdominal discomfort. A large degree of variability is introduced by the resi- 
dence time of the ascorbate solutions in the colon. Consequently, fecal output 
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might be decreased: as more gas and short-chain fatty acids are produced, 
less osmolite remains in the colon. 28 
To predict the efficacy and tolerability of vitamin C in colonic cleansing 
preparations, future studies might assess the amount of hydrogen produced 
using a breath test and the amount of ascorbate xcreted in stool to anticipate 
stool volume recovery. 
In the present study, the minor changes in electrolyte concentrations 
observed remained within normal limits and were not likely to have been 
related to the presence of vitamin C but rather to that of oral sodium sulfate: 
similar electrolyte changes have been described with this osmotic agent. 4,8,14,29 
Despite a statistically nonsignificant decrease in mean serum bicarbonate con- 
centrations with all 6 preparations (Table V), especially with preparation D, 
which contained 10 g/L of ascorbic acid, the serum bicarbonate concentration 
and blood pH remained within normal ranges. This base deficit appeared to be 
due to the presence of ascorbic acid and to be dose dependent, although the 
latter hypothesis could not be confirmed in the present study. 
Because the taste of sodium ascorbate was less acidic compared with that of 
ascorbic acid based on responses on the Likert scale, combinations of ascorbic 
acid and sodium ascorbate or ascorbic acid alone were tested in the current 
study, resulting in improved acceptance of the preparations that contained 
sodium ascorbate (C, E, and F). Moreover, a slight but statistically nonsignifi- 
cant decrease in the serum bicarbonate concentration did not differ signifi- 
cantly between preparations (Table V). Therefore, preparation C, which was 
found to have efficacy similar to those of preparations D and F, would be 
expected to have a more acceptable taste. 
A few subjects, regardless of preparation i gested, reported thirst and asked to 
drink a large amount (---500 mL) of water after they ingested the second liter of 
preparation. Dehydration might explain this thirst, and might have been evi- 
denced by the observed mean weight loss of up to 1.1 kg (especially with prepara- 
tion D) and the low mean urinary output (330 mL over the 10-hour follow-up 
period vs 610 mL during ingestion), together with a decrease in the serum potas- 
sium concentration a d an increase in the serum sodium concentration. However, 
we hypothesized that when a smaller volume of colonic preparation is required, 
patients might be able to self-monitor their thirst and increase the volume of water 
on an individual basis, thus increasing the acceptability ofa preparation. 
A limitation of this study was the lack of a colonoscopy performed to 
directly assess the quality of colonic cleansing after the ingestion of each 
preparation. However, based on the assumption that a stool volume of ---3 L 
might be predictive of adequate colonic cleansing, 16 the results of the present 
study suggest that adding high-dose vitamin C (10 g/L) and sodium sulfate (7.5 g/L) 
in a 100-g/L PEG solution did not adequately increase stool output and there- 
fore might be inadequate for colonic cleansing before colonoscopy or colonic 
surgery. Further studies testing alternative combinations of osmotic agents 
with higher doses of vitamin C compared with those in the preparations used 
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in the present study are warranted, with or without colonoscopy, depending on 
the study populat ion and design. 
Future pilot studies enrolling specific patient populations, such as elderly 
patients or those with cardiac or renal dysfunction whose salts or stimulant laxa- 
t ives might be restr icted,  are needed.  29-31 Such studies  should  test  prepara-  
tions containing a combinat ion of sodium ascorbate with ascorbic acid rather 
than ascorbic acid alone because the decrease in serum bicarbonate concentra- 
tion might become clinically significant if higher doses of ascorbic acid are used 
alone, based on the results of the current pilot study. Finally, the acceptabi l i ty 
of future combinat ions might be optimized by self-monitored ingestion of water, 
preventing the risk for dehydration. 
CONCLUSIONS 
In this s tudy of 6 colonic cleansing preparat ions in healthy volunteers,  the use 
of high-dose vitamin C as an osmotic agent in addition to PEG did not signifi- 
cantly increase stool output. All 6 preparat ions were well tolerated. 
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